Strategically Plan, Launch & Scale Global Early Access Programmes to Deliver Earlier Patient Access While Navigating Complex Regulatory, Supply & Operational Hurdles
Early Access Programmes have evolved into a critical, but increasingly complex, part of drug development and launch strategy. What was once a reactive pathway is now a strategic lever shaping timelines, evidence generation, and patient access across global markets.
As regulatory expectations intensify, reimbursement timelines stretch and programmes expand across more regions, the need for smarter, earlier and more operationally robust access strategies has never been greater.
That is why the Operationalise: Early Access Programmes Summit Europe had become the essential meeting point for the teams leading this transformation. We brought together 140+ experts across Medical Affairs, Patient Access, Regulatory, Clinical Operations, Supply and Evidence Generation to define what best-in-class early access looked like in 2026 and beyond.
You could've heard directly from senior leaders at UCB, Eisai, Novartis, BeOne Medicines, Alnylam Pharmaceuticals, Genmab, AstraZeneca, Bristol Myers Squibb, Argenx, ACADIA Pharmaceuticals, and more as they shared the decisions, frameworks and lessons shaping the next generation of Early Access Programmes.
Whether you are building your first programme, scaling across regions, or managing a global access portfolio, this was your opportunity to benchmark against the organisations setting the pace globally.
Attending Companies Included